Romiplostim launch date in China

It is understood that in 2022, the National Medical Products Administration has approved Romiplostim (Romiplostim) for domestic marketing, and Japan’s Kyowa Kirin Co. Ltd. Takasaki (Kyowa Kirin Co. Ltd. Romigrastim for injection applied by Plant) may be used for immune thrombocytopenia (ITP). Due to its short time on the market, it is not included in the scope of medical insurance, and domestic purchase channels may be difficult.

Thrombopoietin receptor agonists(TPO-RAs) are a class of platelet growth factors used to treat immune thrombocytopenia (ITP) in children and adults. Romiplostim is a peptideTPO-RA approved for the treatment of ITP in adults and also approved for the treatment of ITP in children 1 year of age and older who have had an inadequate response to corticosteroids, intravenous immune globulin, or splenectomy. Like the small molecule TPO-RA eltrombopag, romiplostim has a high clinical response rate in pediatric patients with ITP, but requires long-term use, possibly indefinitely. The application of TPO-RAs in ITP is supported by ITP as a disease with increased platelet destruction and insufficient platelet production, but TPO-RAs can reverse the production defects and inhibit the pro-apoptotic effects of glycoprotein-specific platelet autoantibodies and lymphocytes on megakaryocyte precursors and megakaryocytes, thereby promoting their survival and platelet production.

The Hong Kong original version of romigrastim may be priced at RMB 10,000 per tube (the price may fluctuate due to exchange rates). The price of the European version of romiplostim the original drug may be 11,000 RMB per pill, the German version may be 9,850 RMB per pill, and the Hong Kong version may be 8,900 RMB per pill (the price may fluctuate due to the exchange rate). The ingredients of the drugs are basically the same. For specific prices and drug details, please consult Yaode’s medical consultant.